Related Experiment Videos
Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists
Robert L Dow1, Ernest S Paight, Steven R Schneider
1Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA. robert_l_dow@groton.pfizer.com
Bioorganic & Medicinal Chemistry Letters
|May 20, 2004
Summary
Researchers developed novel sulfamide-based compounds targeting the human beta(3)-adrenergic receptor (AR). These analogs maintain high potency and selectivity, offering a promising avenue for therapeutic development.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- The human beta(3)-adrenergic receptor (AR) is a key target for various physiological processes.
- Previous compounds like L-796568 have shown activity at the beta(3)-AR, but modifications can improve properties.
Purpose of the Study:
- To synthesize and evaluate novel sulfamide-based analogs of L-796568.
- To assess the biological activity, potency, and selectivity of these new compounds at the human beta(3)-AR.
Main Methods:
- Chemical synthesis of sulfamide-based analogs.
- In vitro biological assays to determine receptor binding and functional activity.
- Selectivity profiling against related adrenergic receptor subtypes (beta(2)-AR and beta(1)-AR).
Main Results:
- A series of sulfamide-based analogs were successfully prepared.
- Compounds demonstrated single-digit nanomolar potencies at the human beta(3)-AR.
- High selectivity was observed for the beta(3)-AR over beta(2)-AR and beta(1)-AR.
Conclusions:
- Sulfamide-based modifications represent a viable strategy for developing potent and selective beta(3)-AR ligands.
- These analogs offer reduced molecular weight while retaining significant biological activity.
- The findings support further investigation of these compounds for potential therapeutic applications targeting the beta(3)-AR.